Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy

The pathogenesis and therapy of shrinking lungs syndrome in patients with systemic lupus erythematosus remains controversial. It has been previously reported that corticosteroid treatment can be effective. We report a patient with shrinking lungs syndrome who presented a good response to inhaled bet...

Full description

Saved in:
Bibliographic Details
Published inLupus Vol. 6; no. 4; p. 412
Main Authors Muñoz-Rodríguez, F J, Font, J, Badia, J R, Miret, C, Barberà, J A, Cervera, R, Ingelmo, M
Format Journal Article
LanguageEnglish
Published England 01.01.1997
Subjects
Administration, Inhalation
Adrenergic beta-Agonists - administration & dosage
Adrenergic beta-Agonists - therapeutic use
Adult
Albuterol - administration & dosage
Albuterol - therapeutic use
Bronchodilator Agents - administration & dosage
Bronchodilator Agents - therapeutic use
Female
Follow-Up Studies
Humans
Lung Diseases - drug therapy
Lung Diseases - etiology
Lung Diseases - physiopathology
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - physiopathology
Pulmonary Ventilation
Radiography, Thoracic
Tomography, X-Ray Computed
Online AccessGet more information

Cover

More Information
Summary:The pathogenesis and therapy of shrinking lungs syndrome in patients with systemic lupus erythematosus remains controversial. It has been previously reported that corticosteroid treatment can be effective. We report a patient with shrinking lungs syndrome who presented a good response to inhaled beta-agonist therapy. Therapeutic approach to this syndrome is discussed.
ISSN:0961-2033
DOI:10.1177/096120339700600413